271504.fig.001a
(a) Zidovudine
271504.fig.001b
(b) Didanosine
271504.fig.001c
(c) Zalcitabine
271504.fig.001d
(d) Stavudine
271504.fig.001e
(e) Lamivudine
271504.fig.001f
(f) Abacavir
271504.fig.001g
(g) Tenofovir
271504.fig.001h
(h) Nelfinavir
271504.fig.001i
(i) Indinavir
271504.fig.001j
(j) Lopinavir/ritonavir
271504.fig.001k
(k) Saquinavir
271504.fig.001l
(l) Nevirapine
271504.fig.001m
(m) Efavirenz
Figure 1: Incidence rates of myocardial infarction according to cumulative exposure to nucleoside/nucleotide analogues (A–G), protease inhibitors (H–K), and nonnucleoside reverse transcriptase inhibitors (L, M). The grey areas indicate the 95% confidence interval. PYFU, person-years of followup. Adapted from Worm et al. [24].